Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...
Banner Image
Mobile banner image

Pfizer Oncology
Development

Overview - by Cancer

Geo Regions

View studies/programs by

Cancer Type Phase
Cancer types
Phases
Study status

Breast Cancer Icon Breast Cancer

Presentation Vepdegestrant (ARV-471)* + Atirmociclib (PF-07220060)

Vepdegestrant (ARV-471)* + Atirmociclib (PF-07220060)

PROTAC® Estrogen Receptor Degrader
CDK4 Inhibitor
Presentation Atirmociclib (PF-07220060)

Atirmociclib (PF-07220060)

CDK4 Inhibitor
Presentation CDK2 Inhibitor + Atirmociclib (PF-07220060)

CDK2 Inhibitor + Atirmociclib (PF-07220060)

PF-07104091
CDK4 Inhibitor
Presentation CDK2 Inhibitor

CDK2 Inhibitor

PF-07104091
orange rotating molecule

Felmetatug vedotin (PF-08046048, SGN-B7H4V)

B7-H4-directed Antibody Drug Conjugate
Presentation KAT6 Inhibitor

KAT6 Inhibitor

PF-07248144
Presentation Vepdegestrant (ARV-471)* + Palbociclib

Vepdegestrant (ARV-471)* + Palbociclib

PROTAC® Estrogen Receptor Degrader
CDK 4/6 Inhibitor
Image representing palbociclib

Palbociclib

CDK 4/6 Inhibitor
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC® Estrogen Receptor Degrader

Gastrointestinal Cancer Icon Gastrointestinal Cancer

Presentation Encorafenib

Encorafenib

BRAF Inhibitor
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor

Genitourinary Cancer Icon Genitourinary Cancer

Presentation Atirmociclib (PF-07220060)

Atirmociclib (PF-07220060)

CDK4 Inhibitor
Presentation Vepdegestrant (ARV-471)* + Atirmociclib (PF-07220060)

Vepdegestrant (ARV-471)* + Atirmociclib (PF-07220060)

PROTAC® Estrogen Receptor Degrader
CDK4 Inhibitor
rotating image for Disitamab vedotin

Disitamab vedotin

HER2-directed Antibody Drug Conjugate
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Presentation Talazoparib + Enzalutamide

Talazoparib + Enzalutamide

PARP Inhibitor
Androgen Receptor Inhibitor
Presentation Mevrometostat (PF-06821497) + Enzalutamide

Mevrometostat (PF-06821497) + Enzalutamide

EZH2 Inhibitor
Androgen Receptor Inhibitor
Presentation KAT6 Inhibitor

KAT6 Inhibitor

PF-07248144
Presentation Sasanlimab

Sasanlimab

Anti-PD-1
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor

Gynecological Cancer Icon Gynecological Cancer

rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor

Hematological Malignancies Icon Hematological Malignancies

rotating image for Brentuximab vedotin

Brentuximab vedotin

CD30-directed Antibody Drug Conjugate
Presentation CD30-directed Antibody-Glucuronide TOP1 Inhibitor Conjugate

CD30-directed Antibody-Glucuronide TOP1 Inhibitor Conjugate

PF-08046044, SGN-35C
rotating gif of SGN-35T

CD30-directed Antibody-Tripeptide MMAE Conjugate

PF-08046045, SGN-35T
image representing elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
image representing elranatamab

Elranatamab + Maplirpacept (TTI-622/PF-07901801)

BCMA-CD3 Bispecific Antibody
SIRPα-IgG4 Fusion Protein
image representing maplirpacept

Maplirpacept (TTI-622/PF-07901801)

SIRPα-IgG4 Fusion Protein
rotating gif for Non-Fucosylated CD70-directed Antibody

Non-Fucosylated CD70-directed Antibody

PF-08046040, SEA-CD70

Melanoma Icon Melanoma

Presentation Encorafenib + Binimetinib

Encorafenib + Binimetinib

BRAF Inhibitor
MEK Inhibitor
rotating image for CD228-directed Antibody-Anticalin® Bispecific Protein

CD228-directed Antibody-Anticalin® Bispecific Protein

PF-08046049, SGN-BB228 

Other or Multiple Cancer Types Icon Other or Multiple Cancer Types

Presentation Vepdegestrant (ARV-471)* + Atirmociclib (PF-07220060)

Vepdegestrant (ARV-471)* + Atirmociclib (PF-07220060)

PROTAC® Estrogen Receptor Degrader
CDK4 Inhibitor
Presentation Atirmociclib (PF-07220060)

Atirmociclib (PF-07220060)

CDK4 Inhibitor
Presentation Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

PF-08046052, SGN-EGFRd2
Presentation BRAFi

BRAFi

PF-07799933, ARRY-440
rotating image for CD228-directed Antibody-Anticalin® Bispecific Protein

CD228-directed Antibody-Anticalin® Bispecific Protein

PF-08046049, SGN-BB228 
Presentation CEACAM5-directed Antibody Drug Conjugate

CEACAM5-directed Antibody Drug Conjugate

PF-08046050, SGN-CEACAM5C
rotating image for Disitamab vedotin

Disitamab vedotin

HER2-directed Antibody Drug Conjugate
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
orange rotating molecule

Felmetatug vedotin (PF-08046048, SGN-B7H4V)

B7-H4-directed Antibody Drug Conjugate
Presentation Integrin alpha-V/beta-8 Antagonist

Integrin alpha-V/beta-8 Antagonist

PF-06940434 
Presentation MEK Brain Penetrant Inhibitor

MEK Brain Penetrant Inhibitor

PF-07799544, ARRY-134
Presentation Mesothelin-Targeted Antibody Drug Conjugate

Mesothelin-Targeted Antibody Drug Conjugate

PF-08052666 (SGN-MesoC2)
Presentation Mevrometostat (PF-06821497)

Mevrometostat (PF-06821497)

EZH2 Inhibitor
Presentation PanKRAS Inhibitor

PanKRAS Inhibitor

PF-07934040
rotating gif of PF-08046054, SGN-PDL1V

PD-L1-directed Antibody Drug Conjugate

PF-08046054, SGN-PDL1V
green molecule rotates

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate

SGN-B6A
Presentation STING Agonist

STING Agonist

PF-07820435
rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor

Thoracic Cancer Icon Thoracic Cancer

Presentation KAT6 Inhibitor

KAT6 Inhibitor

PF-07248144
Presentation Sasanlimab

Sasanlimab

Anti-PD-1
green molecule rotates

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate

SGN-B6A

Efficacy and safety of these products, for the uses identified within, are currently under investigation. Regulatory approval of any of these products or uses is dependent on the completion of the study programs and review by regulatory authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of October 30, 2024.

*Vepdegestrant is being co-developed with Arvinas.

Anticalin® is a registered US trademark of Pieris Pharmaceuticals Gmbh.